Top Employee Participation Stories
Bristol-Myers Squibb buys Mirati for $4.8B, as pharma fixates on cancer drugs
By Ike Swetlitz and Nacha CattanThe takeover comes as sales of BMS's blood cancer drug Revlimid, its 3rd-largest revenue driver, withered in the face of generic rivals and its blockbuster Opdivo is also scheduled to face competition from generics later this decade.










